Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPH3127 tablets in mild to moderate active ulcerative colitis
CTR20230538Phase 2Completed
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing SPH3127 tablets with Placebo tablets (2 arms). Primary endpoints: Symptom remission rate at week 8 and Endoscopic remission rate at week 8. Started Jun 2023; status: completed.
02
Drugs
sitokiren
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20230538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230538.